Novartis Signs US$1.7 B Deal with Bicycle Therapeutics for Cancer Radiopharmaceuticals
By Lucy Haggerty
Pharma Deals Review: Vol 2023 Issue 4 (Table of Contents)
Published: 5 Apr-2023
DOI: 10.3833/pdr.v2023.i4.2777 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Adding to its existing radiopharmaceutical portfolio, Novartis has signed a collaboration with Bicycle Therapeutics to develop, manufacture and commercialise Bicycle® radio-conjugates (BRCs) for multiple agreed upon oncology targets...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS